Drug Guide
Omidenepag Isopropyl
Classification
Therapeutic: Prostaglandin Analogue for Glaucoma and Ocular Hypertension
Pharmacological: EP2 Receptor Agonist
FDA Approved Indications
- Open-angle glaucoma
- Ocular hypertension
Mechanism of Action
Omidenepag isopropyl is a selective EP2 receptor agonist that increases aqueous humor outflow through the uveoscleral pathway, thereby reducing intraocular pressure (IOP).
Dosage and Administration
Adult: 1 drop in the affected eye(s) once daily
Pediatric: Not approved for pediatric use
Geriatric: No specific dose adjustment necessary, but monitor for ocular or systemic side effects
Renal Impairment: No specific dose adjustment needed, but caution in severe impairment
Hepatic Impairment: No specific data; use with caution
Pharmacokinetics
Absorption: Rapid absorption after ophthalmic administration
Distribution: Primarily localized; minimal systemic absorption
Metabolism: Metabolized in the ocular tissues; systemic metabolism not fully characterized
Excretion: Mostly local ocular tissues, minimal systemic excretion
Half Life: Approximately 1.8 hours systemically, but local ocular half-life may vary
Contraindications
- Hypersensitivity to omidenepag isopropyl or any components of the formulation
Precautions
- Use with caution in patients with intraocular inflammation, history of ocular surgery, or susceptible to low blood pressure
Adverse Reactions - Common
- Conjunctival hyperemia (Common)
- Ocular pain or discomfort (Common)
- Mild eye irritation (Common)
Adverse Reactions - Serious
- Corneal edema (Rare)
- Uveitis or inflammation (Rare)
- Increase in intraocular pressure (paradoxical effect) (Rare)
Drug-Drug Interactions
- No significant interactions reported
Drug-Food Interactions
- Not applicable
Drug-Herb Interactions
- Limited data; no known interactions
Nursing Implications
Assessment: Monitor intraocular pressure, ocular surface, and patient tolerance
Diagnoses:
- Risk for ocular infection or injury
- Impaired comfort related to ocular irritation
Implementation: Administer one drop once daily as prescribed, educate on proper eye drop technique
Evaluation: Assess reduction in intraocular pressure and patient adherence
Patient/Family Teaching
- Use medication exactly as prescribed, once daily in affected eye(s)
- Report any eye pain, redness, or vision changes immediately
- Avoid touching the tip of the dropper to the eye or surrounding structures
Special Considerations
Black Box Warnings:
- No black box warnings currently in effect
Genetic Factors: N/A
Lab Test Interference: Minimal to none
Overdose Management
Signs/Symptoms: Systemic absorption may cause hypotension or dizziness
Treatment: Supportive care; no specific antidote. Promptly seek medical attention if overdose suspected.
Storage and Handling
Storage: Store at 15-25°C (59-77°F), away from light and moisture
Stability: Stable until the expiry date on the package when stored properly